social.eyeforpharma.comReuters Events | Pharma

Login Username or e-mail * Password * Forgotten Password? Subscribe | Forgot your password? Close log in window On Demand |Newsletter | Log In Thought leadership and innovation for the Pharmaceutical Industry Search this site Home Topics Commercial Multichannel Patients and Medical Access and Evidence Clinical On Demand Content Webinars White papers Latest videos PharmaPulse Podcasts Events About/contact Contact Us Management Team MenuDigital patient engagement finalists revealed Finalists for Pharma Awards Europe 2024 have been announced for ‘Most Valuable Digital Patient Engagement’, sponsored by Sciensus Access and Evidence How to synthesise real-world evidence and AI to transform patient-driven healthcare Pharmaceutical companies have more real-world data (RWD) than ever. As health records have gone digital, sensors have enabled... Access and Evidence Cell and gene therapy: how to discover and communicate clinical worth Watch the full webinar here. Market access is more complex than ever. It requires a delicate balance of demonstrating value to payers... Latest Multichannel AstraZeneca’s roadmap to an omnichannel customer experience Anonymous (not verified) , ( May 3, 2024 ) Data management and governance efficiencies were at the center of AstraZeneca’s accelerated transition to an omnichannel strategy in a bid to boost engagements with healthcare professionals (HCPs). Patients and Medical Digital patient engagement finalists revealed Lucy Fisher , ( Apr 9, 2024 ) Finalists for Pharma Awards Europe 2024 have been announced for ‘Most Valuable Digital Patient Engagement’, sponsored by Sciensus. Access and Evidence Cell and gene therapy: how to discover and communicate clinical worth Anonymous (not verified) , ( Mar 22, 2024 ) CGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach. Access and Evidence What not to miss on Cell and Gene Therapy stage at Reuters Events: Pharma USA 2024 Lucy Fulford , ( Mar 20, 2024 ) From building a solid value proposition to innovating through collaboration, discover where industry changemakers see the strengths of cell and gene in 2024. Medical Cell and gene therapy: ways to generate evidence to demonstrate value Anonymous (not verified) , ( Feb 23, 2024 ) Although cell and gene therapies (CGTs) are typically expensive products, there are techniques that pharmaceutical companies can execute to underscore why they are worthwhile. More Content Most Popular What not to miss on Cell and Gene Therapy stage at Reuters Events: Pharma USA 2024 Lucy Fulford , ( Mar 20, 2024 ) From building a solid value proposition to innovating through collaboration, discover where industry changemakers see the strengths of cell and gene in 2024. Digital patient engagement finalists revealed Lucy Fisher , ( Apr 9, 2024 ) Finalists for Pharma Awards Europe 2024 have been announced for ‘Most Valuable Digital Patient Engagement’, sponsored by Sciensus. Cell and gene therapy: how to discover and communicate clinical worth Anonymous (not verified) , ( Mar 22, 2024 ) CGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach. Commercial Omnichannel: Getting it right Joseph Constance , ( Feb 2, 2024 ) Success with omnichannel depends on having the right customer data, analytics, and software. Omnichannel strategy: a valuable data source for customer profile generation Anonymous (not verified) , ( Jan 12, 2024 ) An omnichannel approach allows pharma companies to meet customer needs in a targeted way according to any customer’s preferred communication medium. How pharma leaders expedite market access with cutting edge value frameworks Nick Taylor , ( Jan 10, 2024 ) Pharma seeks swift market access for innovative treatments amid evolving regulations, emphasizing collaboration and proactive planning for timely delivery of life-changing therapies. Medical affairs: judicious analysis essential amid large datasets Anonymous (not verified) , ( Dec 19, 2023 ) With the increased use of healthcare technologies, leading to record volumes of data, pharma need to be strategic in extracting insights to drive their marketing strategy. Using data to upgrade patient journeys Anonymous (not verified) , ( Dec 14, 2023 ) Collecting and analyzing patient data can improve all aspects of a patient’s health journey. Data privacy must never be compromised in the process. More Commercial Multichannel AstraZeneca’s roadmap to an omnichannel customer experience Anonymous (not verified) , ( May 3, 2024 ) Data management and governance efficiencies were at the center of AstraZeneca’s accelerated transition to an omnichannel strategy in a bid to boost engagements with healthcare professionals (HCPs). How pharma is empowering key account managers to serve a changing customer base Nick Taylor , ( Feb 7, 2024 ) Key account management (KAM) has become increasingly important to pharma companies as payers and other stakeholders have begun to exert more influence over the products physicians prescribe Using data to upgrade patient journeys Anonymous (not verified) , ( Dec 14, 2023 ) Collecting and analyzing patient data can improve all aspects of a patient’s health journey. Data privacy must never be compromised in the process. Driving next best actions using timely data insights Joseph Constance , ( Oct 9, 2023 ) The omnichannel era presents new opportunities for pharma to more effectively engage with its customers by identifying next best actions (NBAs) driven by more relevant and timely data insights. Meet information demands through modular content Maria Aguirre G... , ( Sep 22, 2023 ) Adopting a modular content strategy allows pharmaceutical companies to reuse and adapt information, speeding up content creation cycles without risking personalization. More Multichannel Access and Evidence Cell and gene therapy: how to discover and communicate clinical worth Anonymous (not verified) , ( Mar 22, 2024 ) CGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach. What not to miss on Cell and Gene Therapy stage at Reuters Events: Pharma USA 2024 Lucy Fulford , ( Mar 20, 2024 ) From building a solid value proposition to innovating through collaboration, discover where industry changemakers see the strengths of cell and gene in 2024. How pharma is unleashing the benefits of real-world evidence along the value chain Joseph Constance , ( Dec 14, 2023 ) Real-world evidence (RWE) is providing a fast track to approval and reimbursement. Tackle social determinants of health via data and community engagement Maria Aguirre G... , ( Nov 3, 2023 ) Social determinants of health can blur the safety and efficacy profiles of therapies, making it critical for the pharmaceutical industry to find ways to ease healthcare barriers. Transform patient-driven healthcare: Synthesize RWE and AI Maria Aguirre G... , ( Sep 7, 2023 ) The future of healthcare is here, and it’s powered by real-world evidence (RWE) and artificial intelligence (AI), transforming patient care and clinical decision-making. More Market Access Patients and Medical Digital patient engagement finalists revealed Lucy Fisher , ( Apr 9, 2024 ) Finalists for Pharma Awards Europe 2024 have been announced for ‘Most Valuable Digital Patient Engagement’, sponsored by Sciensus. Three Pathways to Patient Centricity and Win-Win Stakeholder Outcomes Anonymous (not verified) , ( Feb 2, 2024 ) A round up of a panel discussion at Reuters Events: Pharma 2023, featuring insights from - GSK, Accord Healthcare, Boehringer Ingelheim, CSL Behring, and the Council of Europe How to synthesise real-world evidence and AI to transform patient-driven healthcare Joseph Constance , ( Feb 2, 2024...